天然抗菌肽的研究进展及应用前景

天然抗菌肽是生物体内经诱导产生的一种具有抗菌活性的小分子多肽,来源广泛。目前已从多种物种中分离纯化出千余种抗菌肽,其分子量大约在3～6kD之间,由20～60个氨基酸残基组成。天然抗菌肽具有多种生物活性,如抗细菌、抗真菌、抗病毒和抗癌细胞等作用。综述了天然抗菌肽的分类、生物活性及其作用机理和应用前景。     

抗菌肽的作用机制、生物活性及应用研究进展

抗菌肽广泛存在于生物界,是辅助生物机体抵抗外来病原体入侵的重要防御分子。抗菌肽不仅能抑制、杀灭多种细菌,而且具有抗真菌、抗寄生虫、抗病毒、抗肿瘤和免疫调节等生物学活性。抗菌肽的作用机制与传统抗生素不同,不仅具有广谱抗微生物作用,而且不易诱导机体产生耐药性,因此,在治疗临床耐药菌株方面具有极大的开发潜力。     

抗菌肽构效关系及其表达策略研究进展

抗菌肽(antim icrobial peptides)是一类具有抗菌活性短肽的总称,广泛分布于原核生物与包括人类在内的真核生物体内,是宿主免疫防御系统中的重要组成部分。研究表明,抗菌肽除具有抗病毒、抗细菌、抗真菌作用外,还具有抗肿瘤作用。现从抗菌肽的结构特点与抗菌机制出发,对其构效关系及表达策略进行综述。     

昆虫抗菌肽的生理活性及其转基因应用前景

昆虫抗菌肽是昆虫免疫后存在于血淋巴中的一类活性肽。根据分子的结构可分为 5类 :天蚕素类、昆虫防御素、富含脯氨酸或精氨酸的抗菌肽、富含甘氨酸的抗菌肽、抗真菌肽。且具有广谱的抗菌、抗病毒、抑制肿瘤的生物活性。概述了昆虫抗菌肽的基因的克隆与表达及转基因研究方面的进展 ,并展望了抗菌肽在基因工程中的应用前景     

昆虫抗茵肽的生理活性及其转基因应用前景

昆虫抗菌肽是昆虫免疫后存在于血淋巴中的一类活性肽.根据分子的结构可分为5类天蚕素类、昆虫防御素、富含脯氨酸或精氨酸的抗菌肽、富含甘氨酸的抗菌肽、抗真菌肽.且具有广谱的抗菌、抗病毒、抑制肿瘤的生物活性.概述了昆虫抗菌肽的基因的克隆与表达及转基因研究方面的进展,并展望了抗菌肽在基因工程中的应用前景.     

抗菌肽及其应用研究进展

抗菌肽是生物防御系统产生的一类对抗外源性病原体的肽类物质,具有抗细菌、真菌、霉菌、病毒、原虫、癌细胞等多种活性,具有广阔的应用前景。本文就抗菌肽的分类、理化特征、结构、作用机制、基因工程、应用前景及存在问题等方面进行了简要综述。     

新型抗菌肽——表面活性素、伊枯草菌素和丰原素

表面活性素（surfactin）、伊枯草菌素（iturin）和丰原素（fengycin）是一类主要由革兰阳性芽胞杆菌通过非核糖体合成途径产生的抗菌肽,一般是由1个β-羟基脂肪酸与7～10个氨基酸肽链以酰胺键连接而成的环肽,具有抗细菌、抗真菌、抗病毒、抗肿瘤等生物活性,在医疗方面具有良好的应用前景。目前,人们对这3种新型抗菌肽在医药领域中的研究进展所知甚少,故本文对其发现历史、结构特点、作用机制、生物合成和应用价值进行阐述,为后续研究提供借鉴。     

海洋天然活性产物Fascaplysin 的研究进展

Fascaplysin 是从海绵中发现的一种海洋天然活性产物, 具有抗肿瘤、抗细菌、抗真菌、抗病毒、抗疟疾、抑制胆碱酯酶等多种生物活性。近年来,Fascaplysin 被发现能选择性抑制抗肿瘤靶标——细胞周期蛋白依赖性激酶4, 因而备受关注。综述Fascaplysin 的抗肿瘤机制、全合成及结构改造的研究进展。     

微生物源抗菌肽研究概况

抗菌肽是广泛存在于生物体内的一种小分子多肽,具有分子量小、高效、稳定、作用机制独特和不易产生耐药性等特点,对细菌、真菌、寄生虫、病毒以及肿瘤细胞均有抑制作用。介绍了微生物来源,尤其是细菌源抗菌肽的结构特点、生物活性、作用机制及其在感染性疾病中的应用情况。     

天蚕素类抗菌肽分子设计研究进展

天蚕素是一类由31~39个氨基酸残基组成的阳离子型线性α螺旋抗菌肽,具有抗细菌、抗真菌、抗病毒以及抑制肿瘤细胞等生物活性。天蚕素与传统抗生素作用机制不同,具有不易产生耐药性的特点,因此成为解决传统抗生素多重耐药性问题的一个新突破口。然而,天蚕素在抗菌活性、选择性、毒性以及稳定性等方面还存在诸多问题,并且天然天蚕素提取工艺复杂,成本较高,不适合大规模生产,其对细菌的高毒性也限制了原核工程菌的使用。近年来多肽分子设计的研究方法颇受青睐,为解决多肽物质诸多问题开辟了新的途径。针对天蚕素类抗菌肽研究过程中面临的主要问题综述了其分子设计的研究进展。     

The molecular design of a recombinant antimicrobial peptide CP and its in vitro activity

Antibacterial peptides from various sources express different antibacterial activity. In order to obtain a high activity antibacterial peptide, the sequences of four antimicrobial peptides--Protegrin-1, 4 kDa Scorpion Defensin, Metalnikowin-2A and Sheep Myeloid Antibacterial Peptide SMAP-29--were exploited to generate a synthetic antimicrobial peptide cp gene, which was then cloned into the expression vector pPICZalpha-A. The constructed recombinant expression vector pPICZalpha-cp was transformed into Pichia pastoris X-33, in which the synthetic antimicrobial peptide (CP) could be expressed under the control of the inducible AOX1 promoter and secreted via the alpha mating factor leader of Saccharomyces cerevisiae. Results showed that recombinant plasmid is highly stable, and In vitro experiments showed that the recombinant antimicrobial peptide CP is heat and acid-stable, and it has high antibacterial activity against several Gram-positive and -negative bacteria. Only 1 microg of the recombinant antimicrobial peptide CP has an antibacterial activity equivalent to 64 U ampicillin. Thus, this recombinant antimicrobial peptide could serve as an attractive candidate for the development of therapeutic antimicrobial drugs.     

SMAP-29: a potent antibacterial and antifungal peptide from sheep leukocytes

SMAP-29 is a cathelicidin-derived peptide deduced from sheep myeloid mRNA. The C-terminally amidated form of this peptide was chemically synthesized and shown to exert a potent antimicrobial activity. Antibiotic-resistant clinical isolates highly susceptible to this peptide include MRSA and VREF isolates, that are a major worldwide problem, and mucoid Pseudomonas aeruginosa associated with chronic respiratory inflammation in CF patients. In addition, SMAP-29 is also active against fungi, including Cryptococcus neoformans isolated from immunocompromised patients. SMAP-29 causes significant morphological alterations of the bacterial surfaces, as shown by scanning electron microscopy, and is also hemolytic against human, but not sheep erythrocytes. Its potent antimicrobial activity suggests that this peptide is an excellent candidate as a lead compound for the development of novel antiinfective agents.     

复合抗菌肽PL在毕赤酵母中的分泌表达及其活性研究

为了获得抗菌活性较强的抗菌肽,将几种抗菌肽串联起来在毕赤酵母中表达,并比较其与单独抗菌肽的抑菌活性。以GenBank中的Protegrin-1(PG-1)、ScorpionDefensin(SD)、Metalnikowin-2A和SheepMyeloidAntibacterialPeptide(SMAP-29)(序列号分别为AAB27599,AAAB27538、P80409和P49928)成熟肽段作为模板序列,根据巴斯德毕赤氏酵母(P.pastoris)偏好密码子,设计并人工合成复合抗菌肽pl基因,同时用SOE法获得ScorpionDefensin的基因,分别克隆到pPICZαA载体中,转化P.pastoris受体菌X-33,在醇氧化酶(AOX)启动子调控下,复合抗菌肽PL及SD均获得表达。体外抑菌试验检测复合抗菌肽PL与单独的蝎子防御素SD的热稳定性、酸稳定性、最低抑菌浓度等,结果显示复合抗菌肽PL及SD具有很强的热酸稳定性,而针对不同的细菌,复合抗菌肽则表现出了强于单独的SD的活性,特别是对大肠杆菌。上述结果说明了该复合抗菌肽具有很好的开发前景。     

抗菌肽及其临床应用研究进展

抗菌肽是生物体在抵抗病原微生物的防御反应过程中产生的一类具有抗微生物活性的小分子多肽。抗菌肽是机体天然免疫系统的重要组成部分,具有广谱的抗革兰氏阳性、阴性菌活性,对真菌、某些有包膜的病毒、寄生虫以及肿瘤细胞也有抑制活性。抗菌肽具有不同于传统抗生素的独特抗菌机制,病原菌不宜对其产生耐药性,有可能成为一种新的抗生素替代品。介绍了抗菌肽的来源与分类、理化特性与生物学活性,并重点阐述其最新的临床应用进展。     

A comparative study on the interactions of SMAP-29 with lipid monolayers

This work investigates the discrimination of lipid monolayers by the ovine antimicrobial peptide SMAP-29 and compares it to that of the human LL-37 peptide. Fluid phospholipid monolayers were formed in a Langmuir trough and subsequently studied with the X-ray scattering techniques of X-ray reflectivity and grazing incidence X-ray diffraction. Any changes in the phospholipid structure after injection of peptide under the monolayer were considered to be due to interactions between the peptides and lipids. The data show that SMAP-29 discriminates against negatively charged phospholipids in a similar way to LL-37. However, it is even more interesting to note that despite a higher concentration of SMAP-29 near the monolayer, ensured by its greater charge as compared to LL-37, the amount of SMAP-29 needed to observe monolayer disruption was around three and a half times the number of molecules of LL-37 used to see similar changes with the same system. This result suggests that the structure, amino acid sequence or size of the peptide may well be as important as electrical charge and therefore gives many implications for the further study of antimicrobial peptides with regards to novel drug design and development.     

Bacterial killing mechanism of sheep myeloid antimicrobial peptide-18 (SMAP-18) and its Trp-substituted analog with improved cell selectivity and reduced mammalian cell toxicity

To develop short antimicrobial peptide with improved cell selectivity and reduced mammalian cell toxicity compared to sheep myeloid antimicrobial peptide-29 (SMAP-29) and elucidate the possible mechanisms responsible for their antimicrobial action, we synthesized a N-terminal 18-residue peptide amide (SMAP-18) from SMAP-29 and its Trp-substituted analog (SMAP-18-W). Due to their reduced hemolytic activity and retained antimicrobial activity, SMAP-18 and SMAP-18-W showed higher cell selectivity than SMAP-29. In addition, SMAP-18 and SMAP-18-W had no cytotoxicity against three different mammalian cells such as RAW 264.7, NIH-3T3 and HeLa cells even at 100 μM. These results suggest that SMAP-18 and SMAP-18-W have potential for future development as novel therapeutic antimicrobial agent. Unlike SMAP-29, SMAP-18 and SMAP-18-W showed relatively weak ability to induce dye leakage from bacterial membrane-mimicking liposomes, N-phenyl-1-napthylamine (NPN) uptake and o-nitrophenyl-β-galactoside (ONPG) hydrolysis. Similar to SMAP-29, SMAP-18-W led to a significant membrane depolarization (>80 %) against Staphylococcus aureus at 2 × MIC. In contrast, SMAP-18 did not cause any membrane depolarization even at 4 × MIC. In confocal laser scanning microscopy, we observed translocation of SMAP-18 across the membrane in a non-membrane disruptive manner. SMAP-29 and SMAP-18-W were unable to translocate the bacterial membrane. Collectively, we propose here that SMAP-29 and SMAP-18-W kill microorganisms by disrupting/perturbing the lipid bilayer and forming pore/ion channels on bacterial cell membranes, respectively. In contrast, SMAP-18 may kill bacteria via intracellular-targeting mechanism.     

Cathelicidins: family of antimicrobial peptides. A review

Cathelicidins are small, cationic, antimicrobial peptides found in humans and other species, including farm animals (cattle, horses, pigs, sheep, goats, chickens, rabbits and in some species of fish). These proteolytically activated peptides are part of the innate immune system of many vertebrates. These peptides show a broad spectrum of antimicrobial activity against bacteria, enveloped viruses and fungi. Apart from exerting direct antimicrobial effects, cathelicidins can also trigger specific defense responses in the host. Their roles in various pathophysiological conditions have been studied in mice and humans, but there are limited information about their expression sites and activities in livestock. The aim of the present review is to summarize current information about these antimicrobial peptides in farm animals, highlighting peptide expression sites, activities, and future applications for human and veterinary medicine.     

Mechanisms of action of ostrich beta-defensins against Escherichia coli

To understand their mechanism of antimicrobial activity against Gram-negative bacteria, ostrich beta-defensins, ostricacins-1 and 2 (Osp-1 and Osp-2), were compared with those of sheep myeloid antimicrobial peptide (SMAP)-29 and human neutrophil peptide (HNP)-1, well-characterized sheep alpha-helical and human alpha-defensin peptides, respectively. Fluorescence-based biochemical assays demonstrated that the ostricacins bound lipopolysaccharides and disrupted both outer and cytoplasmic membrane integrity. The ostricacins' permeabilizing ability was weaker than that of SMAP-29, but stronger than HNP-1. As ostricacins have previously shown the ability to inhibit bacterial growth, these peptides were suggested to be bacteriostatic to Gram-negative bacteria, which are caused by the interaction between the peptides and cytoplasmic targets causing the inhibition of DNA, RNA, and protein synthesis as well as enzymatic activities. These findings indicated promising possibilities for the peptides to be used in the development of therapeutic and topical products.     

Antifungal mechanism of SMAP-29 (1-18) isolated from sheep myeloid mRNA against Trichosporon beigelii

The antifungal activity and mechanism of SMAP-29 (1-18) (SMAP-29), a cathelicidin-derived antimicrobial peptide deduced from N-terminal sequence of sheep myeloid mRNA, were investigated. SMAP-29 displayed a strong antifungal activity against various fungi. To understand the antifungal mechanism(s) of SMAP-29, we examined the interaction of SMAP-29 with the pathogenic fungus Trichosporon beigelii. Confocal microscopy showed that SMAP-29 was localized in the plasma membrane. The antifungal effects of SMAP-29 were further confirmed by using 1,6-diphenyl-1,3,5-hexatriene (DPH) as a plasma membrane probe. Flow cytometric analysis revealed that SMAP-29 acted in an energy-dependent manner. This interaction is also dependent on the ionic environment. Furthermore, SMAP-29 caused significant morphological changes when testing the membrane disrupting activity using liposomes (phosphatidylcholine/cholesterol; 10:1, w/w), as shown by scanning electron microscopy. The results suggest that SMAP-29 may exert its antifungal activity by disrupting the structure of cell membranes, via direct interaction with the lipid bilayers and irregularly disrupted fungal membranes in an energy- and salt-dependent manner.     

Outer membrane lipoprotein Lpp is Gram-negative bacterial cell surface receptor for cationic antimicrobial peptides

Antimicrobial peptides/proteins (AMPs) are important components of the host innate defense mechanisms. Here we demonstrate that the outer membrane lipoprotein, Lpp, of Enterobacteriaceae interacts with and promotes susceptibility to the bactericidal activities of AMPs. The oligomeric Lpp was specifically recognized by several cationic α-helical AMPs, including SMAP-29, CAP-18, and LL-37; AMP-mediated bactericidal activities were blocked by anti-Lpp antibody blocking. Blebbing of the outer membrane and increase in membrane permeability occurred in association with the coordinate internalization of Lpp and AMP. Interestingly, the specific binding of AMP to Lpp was resistant to divalent cations and salts, which were able to inhibit the bactericidal activities of some AMPs. Furthermore, using His-tagged Lpp as a ligand, we retrieved several characterized AMPs, including SMAP-29 and hRNase 7, from a peptide library containing crude mammalian cell lysates. Overall, this study explores a new mechanism and target of antimicrobial activity and provides a novel method for screening of antimicrobials for use against drug-resistant bacteria.